openPR Logo
Press release

Peripheral Arterial Disease Pipeline Drugs Report 2025 by DelveInsight: Exploring Breakthrough Therapies and Advancements Shaping the Global Healthcare Landscape

09-30-2025 08:00 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Peripheral Arterial Disease Pipeline Drugs Report 2025

DelveInsight's "Peripheral Arterial Disease Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Peripheral Arterial Disease pipeline landscape. It covers the Peripheral Arterial Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peripheral Arterial Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Peripheral Arterial Disease Pipeline? Click here to explore the therapies and trials making headlines @ Peripheral Arterial Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Peripheral Arterial Disease Pipeline Report

* On 09 September 2025, Cell Biopeutics Resources Sdn Bhd announced a study is to observe the efficacy and safety of intramuscular administration of Stempeucel Registered in Malaysian patients with critical limb ischemia (CLI) due to peripheral arterial disease.
* DelveInsight's Peripheral Arterial Disease Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Peripheral Arterial Disease treatment.
* The leading Peripheral Arterial Disease Companies such as AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics and others.
* Promising Peripheral Arterial Disease Therapies such as Renexin CR 200/160mg, Aspirin 100mg, Actovegin, Dotarem, Gadovist, Propionyl-L-carnitine Tablets, edoxaban, Clopidogrel, Aspirin and others.

Want to know which companies are leading innovation in Peripheral Arterial Disease? Dive into the full pipeline insights @ Peripheral Arterial Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Peripheral Arterial Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Peripheral Arterial Disease Pipeline Report also highlights the unmet needs with respect to the Peripheral Arterial Disease.

Peripheral Arterial Disease Overview

Peripheral Arterial Disease (PAD) is a circulatory condition where narrowed arteries reduce blood flow to the limbs, commonly affecting the legs. It is primarily caused by atherosclerosis, where fatty deposits build up in the artery walls, restricting blood flow. Symptoms include leg pain during walking (claudication), numbness, or non-healing wounds. PAD increases the risk of heart attack, stroke, and can lead to severe complications like limb amputation if untreated. It is a condition characterized by the narrowing or blockage of peripheral arteries, most commonly in the legs, due to atherosclerosis.

Peripheral Arterial Disease Emerging Drugs Profile

* Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.

* ACP 01: Hemostemix

ACP-01 is Hemostemix's lead product, designed as an autologous cell therapy for regenerating damaged tissues in patients with critical limb ischemia (CLI) and other vascular diseases. The treatment uses the patient's own stem cells, specifically angiogenic cell precursors (ACPs), which are harvested, processed, and then re-injected into areas of poor circulation. These ACPs promote the growth of new blood vessels, aiming to restore blood flow and prevent amputations. ACP-01 has received orphan drug designation from the FDA and has shown promise in clinical trials, particularly for patients with no alternative treatment options. Currently, the drug is in the Phase II stage of its development for the treatment of Peripheral Arterial Disease.

* Revacept: AdvanceCor

Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.

If you're tracking ongoing Peripheral Arterial Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Peripheral Arterial Disease Treatment Drugs [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Peripheral Arterial Disease Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral Arterial Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Arterial Disease Treatment.
* Peripheral Arterial Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Peripheral Arterial Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral Arterial Disease market.

Peripheral Arterial Disease Companies

AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics and others.

Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Peripheral Arterial Disease Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

From emerging drug candidates to competitive intelligence, the Peripheral Arterial Disease Pipeline Report covers it all - check it out now @ Peripheral Arterial Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Peripheral Arterial Disease Pipeline Report

* Coverage- Global
* Peripheral Arterial Disease Companies- AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics and others.

* Promising Peripheral Arterial Disease Therapies- Renexin CR 200/160mg, Aspirin 100mg, Actovegin, Dotarem, Gadovist, Propionyl-L-carnitine Tablets, edoxaban, Clopidogrel, Aspirin and others.

* Peripheral Arterial Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Peripheral Arterial Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Peripheral Arterial Disease Treatment landscape in this detailed analysis @ Peripheral Arterial Disease Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Peripheral Arterial Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Peripheral Arterial Disease - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Peripheral Arterial Disease Collaboration Deals
* Late Stage Products (Phase III)
* Semaglutide: Novo Nordisk
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ACP 01: Hemostemix
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Revacept: AdvanceCor
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Peripheral Arterial Disease Key Companies
* Peripheral Arterial Disease Key Products
* Peripheral Arterial Disease Unmet Needs
* Peripheral Arterial Disease Market Drivers and Barriers
* Peripheral Arterial Disease Future Perspectives and Conclusion
* Peripheral Arterial Disease Analyst Views
* Peripheral Arterial Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peripheral-arterial-disease-pipeline-drugs-report-2025-by-delveinsight-exploring-breakthrough-therapies-and-advancements-shaping-the-global-healthcare-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peripheral Arterial Disease Pipeline Drugs Report 2025 by DelveInsight: Exploring Breakthrough Therapies and Advancements Shaping the Global Healthcare Landscape here

News-ID: 4204546 • Views:

More Releases from ABNewswire

CopperJoint x Paulina Jayne: The Official Launch of the Pink Sock Collection, Celebrating Movement, Joy, and Everyday Confidence
CopperJoint x Paulina Jayne: The Official Launch of the Pink Sock Collection, Ce …
CopperJoint proudly announces the nationwide release of its new Pink Sock Collection, a movement-inspired collaboration with Nashville singer-songwriter Paulina Jayne. Combining expressive style with meaningful daily motivation, the long pink compression socks feature two signature woven message bands - "KEEP GOING" and "JOY IN MOTION." This collection marks an exciting moment for women that not only looks good, but also lifts the spirit. An Inspired Partnership with Purpose The collaboration began with
TCL Offers Unmatched Discounts on NXTPAPER 11 Gen 2 Tablets for a Limited Time
TCL Offers Unmatched Discounts on NXTPAPER 11 Gen 2 Tablets for a Limited Time
Image: https://www.abnewswire.com/upload/2025/11/7d28d258c990d6d6d333a09d1195a4d9.jpg TCL is making eye comfort more affordable than ever this Black Friday, with both configurations of its NXTPAPER 11 Gen 2 tablet [https://www.amazon.com/dp/B0FG7FRDPL?maas=maas_adg_F465400792B3CDBEB55FE9291F5841A8_afap_abs&ref_=aa_maas&tag=maas] seeing record-low prices on Amazon. From now through December 1, the 64 GB version is down to $159.99 (36% off), and the 128 GB version is just $179.99 (38% off). The NXTPAPER 11 Gen 2 stands out for its paper-like 11-inch Full HD+ display, powered by TCL's
TCL offers exceptional deal making NXTPAPER 11 Plus tablet affordable under 300$
TCL offers exceptional deal making NXTPAPER 11 Plus tablet affordable under 300$
If you're looking for a tablet that balances performance, comfort, and value, the NXTPAPER 11 Plus from TCL [https://www.amazon.com/dp/B0FLJMFNR7?maas=maas_adg_5AF2681E26EC62C74DF5C1C72CE6A9DD_afap_abs&ref_=aa_maas&tag=maas] is shaping up to be one of this year's smartest buys. With the Black Friday sale underway, you can snag it for just $249.99. Image: https://www.abnewswire.com/upload/2025/11/da5f5868666d07b1b589c9593af7a59f.jpg The 11.5" 2.2K resolution screen uses TCL's proprietary NXTPAPER 4.0 technology, designed to reduce glare, cut blue-light emission, and deliver a more "paper-like" reading experience - ideal
TCL Unveils Exceptional Offer on the Advanced NXTPAPER 11 Gen 2 Tablet
TCL Unveils Exceptional Offer on the Advanced NXTPAPER 11 Gen 2 Tablet
If you're on the lookout for an affordable tablet this Black Friday that's easy on the eyes, the TCL NXTPAPER 11 Gen 2 (128 GB) [https://www.amazon.com/dp/B0FG7QV6SF?maas=maas_adg_1486FCD4C758EA9A35182092D196F846_afap_abs&ref_=aa_maas&tag=maas] is now a serious contender - and with its current deal, it's one to watch. Image: https://www.abnewswire.com/upload/2025/11/1c870dfdbb5765161f68d40f15583e4c.jpg Original price: $289.99 Black Friday price: $179.99 - that's 38% off (about $110 off) Deal runs from November 20 through December 1, 2025, available on Amazon. Eye-friendly NXTPAPER display: The NXTPAPER 4.0

All 5 Releases


More Releases for Peripheral

Key Trends Reshaping the Peripheral Arterial Disease Market: Innovative Shockwav …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Peripheral Arterial Disease Market Size Growth Forecast: What to Expect by 2025? The overall valuation of the peripheral arterial disease sector has seen substantial expansion lately, projected to climb from $4.36 billion recorded in 2024 to reach $4.74 billion by 2025, reflecting an 8.7% compound annual growth rate over
Peripheral Stent Market - Pioneering Solutions for Peripheral Artery Disease: Re …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Peripheral Stent Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Peripheral Stent provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes both intuitive
Peripheral Vascular Devices Market - Empowering Mobility, Preserving Health: Ele …
Newark, New Castle, USA - new report, titled Peripheral Vascular Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Peripheral Vascular Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Peripheral Vascular Devices market. The report offers an overview of
Peripheral Vascular Devices Market Report 2018: Segmentation by Types (Periphera …
Global Peripheral Vascular Devices market research report provides company profile for Abbott Vascular, Bayer Healthcare, Volcano Corporation, Teleflex Medical and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation
Peripheral Vascular Device Market Size, Peripheral Vascular Device Market Share, …
Global Peripheral Vascular Device Market Size is observed to gain traction owing to the factors such as increasing research and development for developing several new product, and rising funding by the private organizations. Request for Sample of This Research Report @ https://bit.ly/2xjOKpC Top Key Player:- Abbott Laboratories Braun Melsungen AG Boston Scientific Corporation R. Brad, Inc. Cardinal Health, Inc. Medtronic plc. Cook Medical, Inc. Teruma Corporation Jude Medical, Inc. The Spectranetics Corporation Volcano Corporation Peripheral vascular disorder (PVD) is a blood circulation disorder
Peripheral Artery Disease Market By Type (Peripheral Angioplasty Balloons, Perip …
Peripheral artery disease is characterized by plaque built up in the arteries carrying blood from heart to legs, arms, and other limbs. Peripheral artery disease in turn also increases the risk of other cardiovascular disorders such as heart attack, coronary heart disease, stroke, and ischemic attack. Request Sample At: https://www.bigmarketresearch.com/request-sample/1633533 The global peripheral artery disease market generated $3,136 million in 2016, and is projected to reach $4,980 million by 2023, registering a